Tiziana Life Sciences Ltd. - ADR
Graf
Godt at vide: Investering i aktier giver typisk et positivt afkast på lang sigt, men indebærer også risiko. Du kan miste dele af eller hele din investering. Tidligere data for denne aktie er ikke en pålidelig indikator for fremtidige afkast. Data fra eksterne udbydere er ikke blevet ændret af Saxo. Se fuld ansvarsfraskrivelse for data.
Om Tiziana Life Sciences Ltd. - ADR
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
/ 